Metabolic syndrome, hyperlipidemia, hypertension, hyperglycemia, sleep apnea
Conditions
Interventions
Trial 1 Oliceridine group:Postoperative analgesia with Oliceridine
Trial 1 Sufentanil group:Postoperative analgesia with Sufentanil
Trial 12 Oliceridine group:Postoperative analgesia with Oliceridine
Trial 2 Sufentanil group:Postoperative analgesia with Sufentanil
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Trial 1: Age 18-65 years, gender is not limited; ASA grade I.-III., BMI>=30kg/m^2; Voluntarily signed informed consent. Trial 2: Age 18-65 years, gender is not limited; ASA grade I.-III., BMI>=30kg/m^2; with sleep apnea syndrome (OSA); Voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: Patients with severe heart and lung diseases, severe liver and kidney dysfunction, history of taking analgesics within 2 weeks before operation, patients with sleep apnea syndrome were excluded in trial 1 Patients participate in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse reactions occurred within 48 hours: respiratory depression, pain, restlessness, nausea, vomiting, hypoxemia (SpO2 < 90%) , pulmonary complications (respiratory depression, pneumonia) , etc. .;Visual analogue scale (VAS) at 1,6,12,24,48 hours postoperatively;Recovery of quality on the third day after surgery;Serum IL-6 and TNF-a concentrations; | — |
Countries
China
Contacts
Public ContactWang Li
The First Hospital of Hebei Medical University
Outcome results
None listed